CURE Pharmaceutical Secures Chinese Patent on its Oral

New Post Public Reply Private Reply Replies (1) Message Board
Lee Adams Lee Adams #8
286
CURE Pharmaceutical [OTCQB:CURR] Secures Chinese Patent on its Oral Thin Films to Treat Erectile Dysfunction

OXNARD, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of Chinese Patent No. ZL201480039313.6. The new patent covers the loading of high amounts of active drug on an oral thin film using its proprietary drug delivery systems, including its lead drug product, CUREfilm Blue™, a soluble thin film for oral administration of sildenafil citrate (Viagra™) to treat erectile dysfunction (ED) in China.

“Securing this key patent supports our global commercialization strategy for CUREfilm Blue as well as follow-on drugs delivered using thin film,” said Rob Davidson, CEO of CURE Pharmaceutical. “We are focused on the Asian market for this first product, and in particular China, a high-demand ED drug market where consumers are early adopters of innovative dosage forms.”

The ED drug market is expected to reach USD $6.5 billion at a 6% compound annual growth rate by 2025, according to QYResearch. The report points out that the Asia Pacific market will be one of the fastest growing markets for ED medicine. Sildenafil is leading the ED drug market worldwide with more than half of all global sales.

The new patent covers methods of preparing edible thin films that can deliver high doses of active ingredients that are encapsulated using lipids to form micelles or liposomes. This enables CURE to differentiate its oral thin film product from sildenafil oral soluble films.

About CURE Pharmaceutical
CURE Pharmaceutical® is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and patient experience through its proprietary drug dosage forms and delivery systems. CURE has an FDA- and DEA- registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform. CUREform includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, an innovative emulsion technology utilizing proprietary encapsulation techniques; and CUREpods™ a novel chewable delivery system. CUREform's combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S, Canada, Israel, and other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.

For more information about CURE Pharmaceutical, please visit its website at www.curepharma.com.

This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contact:
Paulo Acuna
pacuna@olmsteadwilliams.com
310.824.9000

Currenc Group Inc. (CURR) Stock Research Links

CURR Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 56

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 11

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 63

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
FULC, DSGR and OPCH Deals Draw Fresh Shareholder Scrutiny

Updated Category News Views 94

Three proposed transactions have drawn the kind of legal glare that makes shareholders sit up and check the fine print twice. On November 18, 2026, Halper Sadeh LLC said it was investigating deals involving Fulcrum Therapeutics, Distribution Solutions Group, and Option Care Health for possible federal securities-law violations or fiduciary-duty breaches. That is not a...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 234

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 11

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 53

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 253

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 208

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading

Top 5 Most Recently Viewed Articles

Dover Set to Release Q2 2025 Earnings; Join the Conference Call

Updated Category News Views 156

Dover Set to Release Q2 2025 Earnings Dover is gearing up to share its financial results for the second quarter of 2025, scheduled for release at approximately 6:00 a.m. Central time on the upcoming Thursday. This significant event marks a crucial moment for shareholders and analysts alike, as they anticipate insights into the company's performance and strategic moves....

Continue Reading
Investigation of ImmunityBio, Inc. and Shareholder Rights

Updated Category News Views 322

Investigation of ImmunityBio, Inc. In recent developments, Bragar Eagel & Squire, P.C., a well-respected law firm specializing in shareholder rights, has launched an investigation regarding ImmunityBio, Inc. (NASDAQ: IBRX). This probe is geared towards looking into potential legal claims on behalf of long-term shareholders, aiming to ensure their interests are safeguarded...

Continue Reading
Norges Bank's Recent Stake Change in Syensqo Explained

Updated Category News Views 279

Norges Bank's Recent Notification Regarding Stake in Syensqo Norges Bank has recently communicated a significant change regarding its participation in Syensqo. This notification, in line with Belgian transparency laws, reveals that Norges Bank has crossed the 3% voting rights threshold, which is vital for all stakeholders. Understanding the Changes in Voting Rights The...

Continue Reading
ZyVersa Therapeutics Marks Progress with Promising Pipeline Updates

Updated Category News Views 232

Key Developments in ZyVersa's Clinical Journey Important Highlights: Announcement of a Phase 2a proof-of-concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 focusing on patients with diabetic kidney disease planned for the first half of 2025. The regulatory framework for VAR 200’s primary indication, focal segmental glomerulosclerosis (FSGS), is set to...

Continue Reading
Bunion Surgery Market Growth and Leading Players Explained

Updated Category News Views 270

Overview of the Bunion Surgery Market The global Bunion Surgery Market is witnessing substantial growth, projected to increase from US$437.8 million in 2023 to an impressive US$606.1 million by 2029, achieving a CAGR of 5.7%. The surge in demand for surgical treatments primarily arises from the rising incidence of bunions, particularly among the aging population who are...

Continue Reading